Equilibrium, Thermodynamics, and Kinetic Sorption Studies for the Removal of Coomassie Brilliant Blue on Wheat Bran as a Low-Cost Adsorbent

The sorption studies of coomassie brilliant blue (CBB) from aqueous solution have been carried out on wheat bran (WB). Coomassie brilliant blue on wheat bran was used to study the adsorption behavior under various parameters such as pH, dosage amount, and contact time. It was observed that under optimized conditions up to 95.70% dye could be removed from solution onto WB. Langmuir and Freundlich adsorption isotherms were used to elaborate the results. Freundlich model was found to be fitted well and favored multilayer adsorption. The Freundlich constants n and KF were determined as 0.53 and 2.5 × 10−4. Thermodynamic parameters such as ΔG, ΔH, and ΔS studied were taking into account, showed spontaneous and favorable reaction for coomassie brilliant blue on wheat bran. The maximum adsorption capacity qm was found to be 6.410 mg/g. The investigations show that non treated WB is a low-cost adsorbent for the removal of dyes from textile industry effluents

The Role of Self-Accumulated Peptide Amphiphile in Spinal Cord Injury Functional Reclamation

Injection into an experimentally injured spinal cord of a self-assembling peptide amphiphile (PA) that displays an IKVAV epitope reduced glial scarring and improved functional reclamation (Tysseling-Mattiace et al., 2008). Injection of a material that lacked this epitope did not alter outcome suggesting that signaling by the IKVAV epitope was central to the beneficial effects of IKVAV-PA. However the mechanical properties of implanted materials may also alter tissue and cell behavior in vivo (Discher et al., 2005). We therefore explored whether the mechanical properties of PAs might affect outcome after spinal cord injury. By treating animals with a spinal cord injury with different PAs that varied in their mechanical properties without epitope presentation, we found that the beneficial effects of the PAs are primarily dependent upon the presentation of a bioactive epitope presentation rather than the mechanical properties of the PA scaffold

Small Integrin-Binding Ligand N-Linked Glycoproteins (Siblings): A Study On Human Salivary Gland Cancer

Salivary gland carcinomas constitute a rare but deadly group of head and neck cancers, but timely diagnosis is often delayed due to inherent variability in etiology, heterogeneity and histopathological characterization. SIBLINGs are a family of secreted glycophosphoproteins that include osteopontin (OPN), bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), dentin matrix protein-1 (DMP-1), and matrix extracellular phosphoglycoprotein (MEPE). SIBLINGs were first discovered in bone and teeth, and were considered to be exclusively expressed in mineralized tissue. In addition to mineralized tissue, SIBLINGs have now been shown to have variable expression in normal, non-mineralized tissue and in cancers. However, there have been no studies evaluating SIBLING expression in human salivary gland cancers. Our study tested the hypothesis that SIBLINGs, specifically, BSP, DSPP and OPN, would be significantly overexpressed in human salivary gland cancer. We also hypothesized that the cancer secretome would influence SIBLING expression in normal salivary gland cells. Methods: Normal and cancerous human salivary gland tissue obtained from the NDRI were processed using routine immunohistochemistry techniques to evaluate expression of BSP, DSP, and OPN. In addition normal HSG cell line and cancer HTB-41 cell line were evaluated using immunofluorescence techniques to localize expression of BSP, DSP and OPN. Normal HSG, cancer HTB-41 and HSG* cells (normal HSG cells exposed to a cancer HTB-41 secretome) were propagated using routine cell culture techniques for 24, 48, and 72 hours. Western blotting techniques were utilized ii to quantify and compare SIBLING protein expression levels in HSG, HTB-41 and HSG* cells. Normal HSG, cancer HTB-41, and HSG* cells were processed via immunoflourescence in order to observe localization of SIBLINGs. Results: Immunohistochemistry and western blot showed increased expression of SIBLINGs in human salivary gland cancers. Furthermore, immunoflourescence revealed distinct localization of SIBLING proteins in HSG and HTB-41 cell lines. In terms of HSG*, it was found that cells exposed to cancer secretome exhibited similar SIBLING expression to HTB-41. Conclusion: Our studies confirm that SIBLING proteins are selectively expressed in human salivary gland cancer. Also, the cancer secretome is found to affect SIBLING expression in normal cells, similar to HTB-41 cancer cell lines

Equilibrium, Thermodynamics, and Kinetic Sorption Studies for the Removal of Coomassie Brilliant Blue on Wheat Bran as a Low-Cost Adsorbent

The sorption studies of coomassie brilliant blue (CBB) from aqueous solution have been carried out on wheat bran (WB). Coomassie brilliant blue on wheat bran was used to study the adsorption behavior under various parameters such as pH, dosage amount, and contact time. It was observed that under optimized conditions up to 95.70% dye could be removed from solution onto WB. Langmuir and Freundlich adsorption isotherms were used to elaborate the results. Freundlich model was found to be fitted well and favored multilayer adsorption. The Freundlich constants n and KF were determined as 0.53 and 2.5 × 10 −4 . Thermodynamic parameters such as ΔG, ΔH, and ΔS studied were taking into account, showed spontaneous and favorable reaction for coomassie brilliant blue on wheat bran. The maximum adsorption capacity q m was found to be 6.410 mg/g. The investigations show that non treated WB is a low-cost adsorbent for the removal of dyes from textile industry effluents

Comprehensive review of the basic chemical behaviours, sources, processes, and endpoints of trace element contamination in paddy soil-rice systems in rice-growing countries

Rice is the leading staple food for more than half of the world’s population, and approximately 160 million hectares of agricultural area worldwide are under rice cultivation. Therefore, it is essential to fulfil the global demand for rice while maintaining food safety. Rice acts as a sink for potentially toxic metals such as arsenic (As), selenium (Se), cadmium (Cd), lead (Pb), zinc (Zn), manganese (Mn), nickel (Ni), and chromium (Cr) in paddy soil-rice systems due to the natural and anthropogenic sources of these metals that have developed in the last few decades. This review summarizes the sources and basic chemical behaviours of these trace elements in the soil system and their contamination status, uptake, translocation, and accumulation mechanisms in paddy soil-rice systems in major rice-growing countries. Several human health threats are significantly associated with these toxic and potentially toxic metals not only due to their presence in the environment (i.e., the soil, water, and air) but also due to the uptake and translocation of these metals via different transporters. Elevated concentrations of these metals are toxic to plants, animals, and even humans that consume them regularly, and the uniform deposition of metals causes a severe risk of bioaccumulation. Furthermore, the contamination of rice in the global rice trade makes this a critical problem of worldwide concern. Therefore, the global consumption of contaminated rice causes severe human health effects that require rapid action. Finally, this review also summarizes the available management/remediation measures and future research directions for addressing this critical issue

Insights into the mechanisms of arsenic-selenium interactions and the associated toxicity in plants, animals, and humans: a critical review

This review highlights arsenic (As) and selenium (Se) sources in the environment, their uptake in the soil-plant system, interactions between these metals and the associated toxicity in major biological compartments, which may assist in addressing the hazardous impacts associated with As and Se contamination. The interaction between As and Se is a critical factor for a detailed systematic understanding of the transportation, environmental fate, and associated toxicological effects of these metalloids in plants, animals, and humans. Arsenic and Se induce cytotoxicity and genotoxicity through the generation of reactive oxygen species (ROS). Compared to arsenite (AsIII), methylated arsenicals, including methylarsonous acid (MAsIII) and dimethylarsinous acids (DMAsIII), exhibit more cytotoxic and genotoxic potential to inhibit more potent enzymes and activate the protein AP˗1, which is a critical marker of genetic stability. Methylated AsIII and its associated metabolites are well-known potential carcinogens that induce toxicity by blocking Se metabolism pathway. The imbalance of Se compounds can lead to the generation of ROS, which can inhibit or decrease genomic stability. The As and Se nexus also affect cellular signaling through activation of transcription factors such as NFκB and AP-1

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill & Melinda Gates Foundation